Cirsium Biosciences Expands Gene Therapy Role With Dyno Network Partnership and ASGCT Plant-Based AAV Data

Cirsium Biosciences, a private biotech focused on plant-based adeno-associated virus manufacturing, advanced its technology and partnership profile with a series of updates tied to the ASGCT 2026 meeting. The company emphasized that plant-based systems could offer a scalable alternative to traditional HEK293 production for gene therapy vectors.

At ASGCT, Cirsium presented new data showing strong analytical comparability between plant-produced AAV9 and AAV2 capsids and HEK293 reference material, based on LC-MS/MS peptide mapping of post-translational modifications. The results are aimed at easing concerns over the clinical credibility of plant-derived vectors in regulated settings.

Cirsium also highlighted a collaboration with QIAGEN, integrating the QIAcuity digital PCR system for rapid batch screening directly from crude plant lysate in under three hours. This capability is designed to support earlier go/no-go decisions, potentially improving manufacturing efficiency and lowering cost of goods for AAV producers.

In a strategic move, Cirsium was selected as a manufacturing partner in the Dyno Frontiers Network, an ecosystem assembled by Dyno Therapeutics to support next-generation gene therapy and advanced biologics programs. While financial terms and capacity details were not disclosed, the partnership is expected to deepen Cirsium’s role in emerging gene therapy supply chains.

The company’s ASGCT presence also includes a sponsored session with QIAGEN titled “Redefining Gene Delivery Through Plant-Based Manufacturing” and multiple scientific engagements focused on capsid quality attributes. Cirsium is additionally participating in a fireside chat on ARPA-H funding priorities, underscoring its interest in non-dilutive capital alongside prior government funding discussions.

Taken together, the week’s developments point to constructive progress for Cirsium Biosciences in both technological validation and ecosystem integration. These steps may enhance its positioning as a differentiated manufacturing and technology partner within the competitive gene therapy market.